Skip to main content
Back
Watch Compare

FATE THERAPEUTICS INC

Data quality: 100%
FATE
NASDAQ Manufacturing Chemicals
$1.24
▼ $0.03 (-2.36%)
Mkt Cap: 147.65 M
Price
$1.27
Mkt Cap
147.65 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -41.27% annually over 5 years
Negative free cash flow of -112.04 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 9.97%
Capital intensive — 89.57% of revenue goes to capex

Growth

Revenue Growth (5Y)
-41.27%
Below sector avg (1.92%)
Revenue (1Y)-51.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-55.03%
Below sector avg (-54.44%)
ROIC-35.44%
Net Margin-2051.08%
Op. Margin-2222.45%

Safety

Debt / Equity
N/A
Current Ratio7.87
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-1.08 | -1.18
Above sector avg (-1.49)
P/B Ratio0.63
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -1.1 -1.5
P/B 0.6 1.6
ROE % -55.0 -54.4
Net Margin % -2051.1 -41.5
Rev Growth 5Y % -41.3 1.9
D/E — 0.3

Analyst Price Target

9 analysts
Buy
Current
$1.24
+298.7%
Target
$4.94
$2.00
$5.00
$8.00
Forecast
Forward P/E -1.18
Forward EPS -$1.05
Est. Revenue 5.79 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$1.05
-$1.44 – -$0.59
 5.79 M 6
FY2026 -$1.15
-$1.31 – -$0.97
 5.06 M 8

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.27 -$0.27 +0.5%
Q32025 -$0.28 -$0.27 +4.3%
Q22025 -$0.34 -$0.29 +15.8%
Q12025 -$0.38 -$0.32 +15.7%

ETFs Holding This Stock

WDNA WDNA
0.59% weight
CNCR CNCR
0.50% weight
BDSCX BDSCX
0.02% weight
BDSAX BDSAX
0.02% weight
BDSKX BDSKX
0.02% weight
BDSIX BDSIX
0.02% weight
CSGEX CSGEX
0.02% weight
PSGIX PSGIX
0.02% weight
GTTUX GTTUX
0.02% weight
GTTTX GTTTX
0.02% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -51.24% Revenue Growth (3Y) -67.66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -41.27% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6.65 M Net Income (TTM) -136.32 M
ROE -55.03% ROA -38.11%
Gross Margin N/A Operating Margin -2222.45%
Net Margin -2051.08% Free Cash Flow (TTM) -112.04 M
ROIC -35.44% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7.87
Interest Coverage N/A Asset Turnover 0.02
Working Capital 193.14 M Tangible Book Value 234.07 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.08 Forward P/E -1.18
P/B Ratio 0.63 P/S Ratio 22.22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 25.49 Fwd Earnings Yield N/A
FCF Yield -75.88%
Market Cap 147.65 M Enterprise Value 107.03 M
Per Share
EPS (Diluted TTM) -1.15 Revenue / Share 0.06
FCF / Share -0.96 OCF / Share -0.91
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 89.57% FCF Conversion 82.19%
SBC-Adj. FCF N/A Growth Momentum -9.97

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.65 M 13.63 M 63.53 M 96.30 M 55.85 M
Net Income -136.32 M -186.26 M -160.93 M -281.72 M -212.15 M
EPS (Diluted) -1.15 -1.64 -1.64 -2.91 —
Gross Profit — — — — —
Operating Income -147.70 M -210.28 M -190.51 M -308.39 M -216.99 M
EBITDA — — — — —
R&D Expenses 107.83 M 135.00 M 172.60 M 320.45 M 215.52 M
SG&A Expenses — — — — —
D&A 12.90 M 18.96 M 18.28 M 13.76 M 5.85 M
Interest Expense — — — — 0.0
Income Tax 2,000.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 318.94 M 440.69 M 506.22 M 705.56 M 921.46 M
Total Liabilities — — — — —
Shareholders' Equity 207.18 M 318.73 M 368.42 M 483.94 M 678.84 M
Total Debt — — — — —
Cash & Equivalents 46.63 M 36.06 M 41.87 M 61.33 M 133.58 M
Current Assets 208.70 M 291.91 M 331.54 M 502.07 M 633.41 M
Current Liabilities 36.07 M 38.52 M 39.09 M 114.05 M 81.28 M